MaxCyte, Inc. Names Cenk Sumen Chief Scientific Officer
March 09 2022 - 4:15PM
MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT, MXCN), a leading
commercial cell-engineering company focused on providing enabling
platform technologies to advance innovative cell-based research as
well as next-generation cell therapeutic discovery, development and
commercialization, today announced Cenk Sumen, Ph.D., as Chief
Scientific Officer (CSO). With a proven track record of scientific,
technological and business development expertise, Dr. Sumen brings
experience in technology, application and platform assessments, the
development of commercial partnerships and leading
interdepartmental collaboration to accelerate scientific and
technical direction.
“We are thrilled to have Cenk join the MaxCyte
team, as his career has demonstrated a wealth of experience in
science, technology, business development and corporate strategy,”
said MaxCyte CEO, President and Founder Doug
Doerfler. “He is a welcome and important addition to our
leadership team and will be invaluable in helping to support our
partners in the cell therapy space with MaxCyte’s technology. I and
the management team look forward to working with Dr. Sumen to
continually identify growth opportunities to enable the cell
therapy sector and execute on our strategic vision to expand our
scientific and product offerings.”
“I am driven by scientific innovation and
working with visionary companies that truly make a beneficial
impact on the health of humanity,” said Cenk Sumen, CSO at
MaxCyte. “I am eager to ensure MaxCyte’s platforms are
positioned as the premier solution for our customer’s cell
engineering requirements while, at the same time, synergistically
driving scientific and technical direction with collective teams
within the organization to help expand MaxCyte’s position in cell
engineering and the cell therapy and bioprocessing markets.”
Dr. Sumen comes to MaxCyte from Stemson
Therapeutics, where he was the Chief Technology Officer and led all
aspects of technology, scale-up, process development and
automation. Before that, he spent more than a decade focused on
scientific innovation and business development strategy for
companies including Thermo Fisher Scientific and Hitachi Chemical
Advanced Therapeutics Solutions. Dr. Sumen holds a Ph.D. in
Microbiology and Immunology from Stanford University, post-doctoral
training at Harvard and a fellowship at the Cancer Research
Institute, working at Memorial Sloan Kettering Cancer Center under
Nobel Laureate Dr. Jim Allison. Additionally, Dr. Sumen is an
Adjunct Professor in the Department of Chemical and Biomolecular
Engineering at the NYU Tandon School of Engineering. He is
passionate about the opportunity to teach and guide students both
in the classroom and on into successful careers in industry and
academia.
About MaxcyteMaxCyte is a
leading commercial cell-engineering company focused on providing
enabling platform technologies to advance innovative cell-based
research as well as next-generation cell therapeutic discovery,
development and commercialization. Over the past 20 years, we have
developed and commercialized our proprietary Flow Electroporation®
platform, which facilitates complex engineering of a wide variety
of cells. Our ExPERT™ platform, which is based on our Flow
Electroporation technology, has been designed to support the
rapidly expanding cell therapy market and can be utilized across
the continuum of the high-growth cell therapy sector, from
discovery and development through commercialization of
next-generation, cell-based medicines. The ExPERT family of
products includes: four instruments, the ATx™, STx™, GTx™, and
VLx™; a portfolio of proprietary related processing assemblies or
disposables; and software protocols, all supported by a robust
worldwide intellectual property portfolio.
US IR
AdviserGilmartin GroupDavid Deuchler,
CFA |
+1
415-937-5400 ir@maxcyte.com |
US Media
RelationsValerie EnesSeismic |
+1
408-497-8568valerie@teamseismic.com |
Nominated Adviser and
Joint Corporate BrokerPanmure GordonEmma Earl / Freddy
CrossleyCorporate BrokingRupert Dearden |
+44 (0)20 7886 2500 |
UK IR
AdviserConsilium Strategic
CommunicationsMary-Jane ElliottChris Welsh |
+44 (0)203 709
5700maxcyte@consilium-comms.com |
Maxcyte (LSE:MXCN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Maxcyte (LSE:MXCN)
Historical Stock Chart
From Jul 2023 to Jul 2024